PriceTargets.com logo

BioXcel Therapeutics - BTAI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.29
  • Forecasted Upside: 165.64%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$18.93 As of 06/2/2023 06:22 PM ET
▲ +0.78 (4.30%)

This chart shows the closing price for BTAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioXcel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTAI

Analyst Price Target is $50.29
▲ +165.64% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for BioXcel Therapeutics in the last 3 months. The average price target is $50.29, with a high forecast of $76.00 and a low forecast of $22.00. The average price target represents a 165.64% upside from the last price of $18.93.

This chart shows the closing price for BTAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in BioXcel Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2023MizuhoBoost Target$38.00 ➝ $40.00Low
5/9/2023GuggenheimLower Target$50.00 ➝ $46.00Low
3/21/2023HC WainwrightLower TargetBuy$79.00 ➝ $66.00Low
3/10/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$20.00 ➝ $22.00Low
2/21/2023HC WainwrightBoost TargetBuy$73.00 ➝ $79.00Low
2/8/2023MizuhoBoost TargetBuy$24.00 ➝ $38.00Low
1/26/2023The Goldman Sachs GroupBoost TargetNeutral$16.00 ➝ $26.00Low
1/3/2023HC WainwrightLower TargetBuy$85.00 ➝ $73.00Low
12/15/2022MizuhoBoost Target$18.00 ➝ $24.00Low
12/1/2022The Goldman Sachs GroupUpgradeSell ➝ Neutral$16.00Low
11/11/2022GuggenheimLower TargetBuy$28.00 ➝ $25.00Low
11/11/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$75.00 ➝ $76.00Low
11/11/2022Canaccord Genuity GroupBoost TargetBuy$75.00 ➝ $76.00Low
11/11/2022MizuhoLower TargetBuy$19.00 ➝ $18.00Low
8/24/2022HC WainwrightLower TargetBuy$110.00 ➝ $85.00Low
7/6/2022MizuhoInitiated CoverageBuy$19.00N/A
5/23/2022HC WainwrightLower TargetBuy$134.00 ➝ $110.00Low
5/13/2022Canaccord Genuity GroupLower Target$84.00 ➝ $75.00High
5/10/2022Truist FinancialLower Target$125.00 ➝ $71.00High
4/14/2022HC WainwrightBoost TargetBuy$130.00 ➝ $134.00High
4/6/2022Bank of AmericaBoost TargetBuy$78.00 ➝ $80.00High
3/14/2022HC WainwrightLower TargetBuy$140.00 ➝ $130.00High
3/11/2022Canaccord Genuity GroupLower Target$95.00 ➝ $81.00High
2/16/2022UBS GroupLower TargetBuy$88.00 ➝ $25.00Low
11/15/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$55.00 ➝ $24.00High
10/19/2021HC WainwrightReiterated RatingBuy$141.00High
9/17/2021HC WainwrightReiterated RatingBuy$140.00High
8/16/2021Berenberg BankReiterated RatingBuy$70.00High
6/28/2021HC WainwrightLower TargetBuy$176.00 ➝ $140.00Low
6/23/2021Truist FinancialLower TargetBuy$128.00 ➝ $125.00High
6/1/2021HC WainwrightBoost TargetBuy$170.00 ➝ $176.00High
5/11/2021HC WainwrightLower TargetBuy$175.00 ➝ $170.00High
4/9/2021Berenberg BankInitiated CoverageBuy$75.00Low
4/1/2021Truist FinancialLower Target$150.00 ➝ $127.00High
4/1/2021HC WainwrightLower TargetBuy$185.00 ➝ $175.00High
2/1/2021UBS GroupInitiated CoverageBuy$99.00Low
1/6/2021HC WainwrightBoost TargetBuy$175.00 ➝ $185.00N/A
12/28/2020Truist FinancialReiterated RatingBuyN/A
10/30/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00High
9/2/2020Jefferies Financial GroupInitiated CoverageBuy$82.00 ➝ $82.00High
8/17/2020GuggenheimBoost TargetBuy$101.00 ➝ $122.00High
8/17/2020BMO Capital MarketsLower TargetOutperform$104.00 ➝ $95.00High
8/17/2020HC WainwrightLower TargetBuy$200.00 ➝ $175.00High
7/20/2020BMO Capital MarketsBoost TargetOutperform ➝ Positive$64.00 ➝ $104.00High
7/20/2020HC WainwrightBoost TargetBuy$120.00 ➝ $200.00High
7/13/2020Bank of AmericaBoost TargetBuy$53.00 ➝ $63.00High
7/6/2020HC WainwrightReiterated RatingBuy$120.00High
6/24/2020HC WainwrightReiterated RatingBuy$95.00Medium
6/11/2020HC WainwrightReiterated RatingBuy$95.00Medium
6/4/2020GuggenheimInitiated CoverageBuy$101.00High
5/13/2020HC WainwrightReiterated RatingBuy$95.00High
4/28/2020HC WainwrightReiterated RatingBuy$95.00High
4/1/2020Bank of AmericaInitiated CoverageBuy$45.00High
3/19/2020HC WainwrightReiterated RatingBuy$95.00High
3/10/2020BMO Capital MarketsBoost Target$26.00 ➝ $64.00High
2/5/2020HC WainwrightReiterated RatingBuy$30.00High
1/16/2020BMO Capital MarketsReiterated RatingOutperform ➝ Positive$26.00High
1/8/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $30.00High
12/30/2019HC WainwrightInitiated CoverageBuy$25.00High
12/11/2019HC WainwrightReiterated RatingBuy$25.00High
11/20/2019HC WainwrightReiterated RatingBuy$25.00Medium
11/12/2019SunTrust BanksInitiated CoverageBuy$24.00High
9/18/2019BMO Capital MarketsSet TargetBuy$21.00Low
8/21/2019HC WainwrightSet TargetBuy$25.00Low
6/5/2019HC WainwrightSet TargetBuy$25.00Low
5/28/2019HC WainwrightSet TargetBuy$25.00Medium
3/26/2019HC WainwrightSet TargetBuy$25.00High
3/5/2019HC WainwrightSet TargetBuy$25.00Medium
2/5/2019HC WainwrightSet TargetBuy$25.00High
1/4/2019HC WainwrightReiterated RatingBuy$25.00Medium
12/12/2018HC WainwrightReiterated RatingBuy$25.00Medium
8/1/2018HC WainwrightReiterated RatingBuy$25.00Low
6/12/2018HC WainwrightReiterated RatingBuy$25.00High
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/4/2023
  • 5 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
4/3/2023
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 3 very positive mentions
  • 40 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 3 very positive mentions
  • 40 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

BioXcel Therapeutics logo
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in developing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. It also focuses on utilizing cutting-edge technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Read More

Today's Range

Now: $18.93
Low: $17.56
High: $19.00

50 Day Range

MA: $21.41
Low: $16.69
High: $28.58

52 Week Range

Now: $18.93
Low: $8.80
High: $34.13

Volume

629,438 shs

Average Volume

507,001 shs

Market Capitalization

$552.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of BioXcel Therapeutics?

The following sell-side analysts have issued reports on BioXcel Therapeutics in the last year: Canaccord Genuity Group Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Mizuho, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for BTAI.

What is the current price target for BioXcel Therapeutics?

7 Wall Street analysts have set twelve-month price targets for BioXcel Therapeutics in the last year. Their average twelve-month price target is $50.29, suggesting a possible upside of 177.1%. Canaccord Genuity Group Inc. has the highest price target set, predicting BTAI will reach $76.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $22.00 for BioXcel Therapeutics in the next year.
View the latest price targets for BTAI.

What is the current consensus analyst rating for BioXcel Therapeutics?

BioXcel Therapeutics currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BTAI will outperform the market and that investors should add to their positions of BioXcel Therapeutics.
View the latest ratings for BTAI.

What other companies compete with BioXcel Therapeutics?

Other companies that are similar to BioXcel Therapeutics include GH Research, Lexicon Pharmaceuticals, Aldeyra Therapeutics, Phibro Animal Health and Harrow Health. Learn More about companies similar to BioXcel Therapeutics.

How do I contact BioXcel Therapeutics' investor relations team?

BioXcel Therapeutics' physical mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company's listed phone number is (475) 238-6837 and its investor relations email address is [email protected]. The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com. Learn More about contacing BioXcel Therapeutics investor relations.